دورية أكاديمية
BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia
| العنوان: | BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia |
|---|---|
| المؤلفون: | Bilbao Sieyro, Cristina, Rodríguez-Medina, Carlos, Florido, Yanira, Stuckey, Ruth, Sáez, María Nieves, Sánchez Sosa, José Santiago, González Martín, Jesús María, Santana, Guillermo, González-Pérez, Elena, Cruz-Cruz, Naylén, Fernández, Rosa, Molero Labarta, María Teresa, Gómez Casares, María Teresa |
| المساهمون: | BU-MED |
| المصدر: | Diagnostic [ ISSN 2075-4418], v. 10 (12), (Diciembre 2020) |
| سنة النشر: | 2020 |
| المجموعة: | Universidad de Las Palmas de Gran Canaria: Acceda |
| مصطلحات موضوعية: | 32 Ciencias médicas, 320101 Oncología, Investigación, Acute myeloid leukemia, BCL2 inhibitors, Biomarkers, Patient outcome, Induction therapy, Molecular diagnostics |
| الوصف: | Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remission (CR) and relapse (RL). Levels increased significantly at relapse (mean 1.07 PI/0.96 CR vs. 2.17 RL, p = 0.05/p = 0.03). In multivariate analysis, high BCL2-Dx were marginally associated with worse progression-free survival, while high PI levels or at CR had an independent negative impact on outcome (PI: HR 1.58, p = 0.014; CR: HR 1.96, p = 0.008). This behavior of high PI or CR BCL2 levels and increased risk was maintained in a homogeneous patient subgroup of age <70 and intermediate cytogenetic risk (PI: HR 2.44, p = 0.037; CR: HR 2.71, p = 0.049). Finally, for this subgroup, high BCL2 at relapse indicated worse overall survival (OS, HR 1.15, p = 0.05). In conclusion, high BCL2 levels PI or at CR had an independent negative impact on patient outcome. Therefore, BCL2 expression is a dynamic marker that may be useful during AML patient follow up, and BCL2 levels at PI and/or CR may influence response to anti-BCL2 therapy. ; 8 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2075-4418 |
| العلاقة: | Diagnostics; 10; http://hdl.handle.net/10553/106533Test; 12; Sí |
| DOI: | 10.3390/diagnostics10121048 |
| الإتاحة: | https://doi.org/10.3390/diagnostics10121048Test http://hdl.handle.net/10553/106533Test |
| رقم الانضمام: | edsbas.5B4DE1C4 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20754418 |
|---|---|
| DOI: | 10.3390/diagnostics10121048 |